Cardiovascular Health
The LuNa Program
Cardiovascular health remains the world’s leading cause of death.
BioShift’s cardiovascular program evaluates natural, non-pharmaceutical strategies to improve arterial health and reduce plaque buildup. The LuNa Program, named for Lumbrokinase and Nattokinase, explores the potential of these natural enzymes and nutrient combinations to support healthy blood flow and improve vascular health. Our research focuses on understanding how these compounds may influence the biological processes that contribute to plaque formation and stability in the arteries.
Contributions to this program help our team continue foundational work that may inform safer, more accessible strategies for promoting cardiovascular health. Your support sustains early-stage testing, laboratory analysis , and ongoing data collection that inform safe, accessible approaches to heart health.
-
Participants in our LuNa Program undergo AI-powered coronary CT angiography (CCTA) to measure plaque volume and composition at baseline and follow-up.
Cleerly® imaging quantifies even small changes in soft plaque, providing clear insight into how supplementation may affect vessel health.
-
Through supplementation, we aim to utilize the complex biological action of these selected enzymes.
Lumbrokinase
Lumbrokinase is a group of fibrinolytic enzymes extracted from earthworms. It has been used in Asia for decades as a circulatory health supplement and is known for its ability to enhance the natural breakdown of blood clots.
Nattokinase
Nattokinase is a naturally occurring enzyme derived from natto, a traditional Japanese fermented soybean food. Like lumbrokinase, it exhibits fibrinolytic properties, but also supports cardiovascular health through lipid metabolism.
